ASCO: combo antibody therapy effective for melanoma

May 17, 2013
ASCO: combo antibody therapy effective for melanoma
Concurrent use of two immune checkpoint antibodies -- ipilimumab and nivolumab -- may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in advance of the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in advance of the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.

Jedd D. Wolchok, M.D., Ph.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues enrolled patients who had received no more than three prior treatments. Patients received intravenous nivolumab and concurrently for four doses, followed by nivolumab alone. Additionally, in two other study arms, patients who had undergone prior ipilimumab treatment received only nivolumab.

The researchers found that, based on the 37 patients treated with concurrent , the objective response rate was 38 percent. In the three concurrent treatment arms that completed the trial, tumor shrinkage rates were 21, 47, and 50 percent, with the highest rates seen in patients treated with the highest dose of both drugs. The responses to therapy were rapid, with three out of four responding patients doing so within the first three months, which is faster than with single-agent ipilimumab. Thirty percent of patients experienced significant of more than 80 percent. Adverse events for concurrent therapy were similar in nature (although some with higher frequency) than those typically seen for the monotherapies and were generally manageable using immunosuppressants.

"The complete and near-complete response rates we're seeing are unprecedented for an in melanoma," Wolchok said in a statement.

Several authors disclosed financial ties to Bristol-Myers Squibb, which funded the study and manufactures ipilimumab and nivolumab.

Explore further: Ipilimumab active in advanced melanoma with brain mets

More information: Abstract
More Information

Related Stories

Ipilimumab active in advanced melanoma with brain mets

March 27, 2012
(HealthDay) -- For some patients with advanced melanoma and brain metastases, ipilimumab is active, according to the results of a phase 2 study published online March 27 in The Lancet Oncology.

Systemic tumor disappearance following local radiation treatment reported in metastatic melanoma patient

March 7, 2012
A rarely seen phenomenon in cancer patients — in which focused radiation to the site of one tumor is associated with the disappearance of metastatic tumors all over the body — has been reported in a patient with ...

Melanoma expert reviews unique adverse events with newly approved drug

August 22, 2012
An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. Kähler, M.D., have published an article ...

Combination antibody therapy shows promise in metastatic melanoma

June 4, 2011
(Medical Xpress) -- A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to ...

Considerable added benefit of ipilimumab in advanced melanoma

November 9, 2012
The humanized antibody ipilimumab (trade name Yervoy) has been approved since August 2011 for the treatment of adult patients with advanced melanoma (black skin cancer) who have already been treated. The term "advanced" means ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.